Venous Thromboembolism Risk Lower among Patients with atopic dermatitis
Venous thromboembolism risk is lower among atopic dermatitis patients versus other immune-mediated inflammatory diseases suggests a new study published in the Journal of the American Academy of Dermatology.
Certain immune-mediated inflammatory diseases (IMIDs) may increase patients’ risk for venous thromboembolisms (VTEs), yet how atopic dermatitis (AD) influences VTE risk remains unclear. Describe venous thromboembolism incidence in patients with atopic dermatitis compared with other IMIDs and unaffected, atopic dermatitis-matched controls. This retrospective, observational, comparative cohort study used Optum® Clinformatics® United States claims data (2010–2019) of adults with atopic dermatitis, rheumatoid arthritis (RA), Crohn’s disease (CD), ulcerative colitis (UC), psoriasis (PsO), psoriatic arthritis (PsA), or ankylosing spondylitis (AS). Unaffected control patients were matched 1:1 with patients with atopic dermatitis. Results: Of 2,061,222 patients with IMIDs, 1,098,633 had atopic dermatitis. Patients with atopic dermatitis had a higher venous thromboembolism incidence (95% CI) than unaffected, atopic dermatitis-matched controls. However, when controlling for baseline VTE risk factors, atopic dermatitis was not associated with increased venous thromboembolism risk. Venous thromboembolism risk was lower in patients with atopic dermatitis versus RA, UC, CD, AS, or PsA; venous thromboembolism risk was similar in patients with psoriasis. atopic dermatitis did not increase venous thromboembolism risk when accounting for underlying risk factors. Atopic dermatitis was associated with lower venous thromboembolism risk compared with several rheumatologic and gastrointestinal IMIDs.
(https://www.sciencedirect.com/science/article/pii/S019096222303400X)
